(NASDAQ:SCLN) shares saw light trading volume with 0 shares changing hands on Tuesday. Trading volume was down 100.00% under the stocks average daily volume.
Investors are a little more bearish on the company lately looking at the change in short interest. The stock experienced a rise in short interest of 23.98% between September 29, 2017 and October 13, 2017. Short shares increased from 568,032 to 704,249 over that period. The days to cover decreased to 1.0 and the percentage of shorted shares was 0.01% on October 13.
These funds have shifted positions in (SCLN). As of quarter end Nationwide Fund Advisors had sold 992 shares trimming its holdings by 2.6%. The value of the investment in SciClone Pharmaceuticals, Inc. decreased from $418,000 to $414,000 a change of 1.0% quarter to quarter. As of the end of the quarter First Trust Advisors Lp had disposed of a total of 11 shares trimming its stake by 0.0%. The value of the investment in (SCLN) went from $454,000 to $462,000 a change of $8,000 quarter over quarter.
As of the end of the quarter Aperio Group, LLC had acquired a total of 14,593 shares growing its position 50.7%. The value in dollars increased from $317,000 to $486,000 increasing 53.3% since the last quarter. Simplex Trading, LLC cut its position by selling 3,600 shares a decrease of 99.4% as of 09/30/2017. Simplex Trading, LLC owns 23 shares worth $0. The total value of its holdings decreased 100.0%.
The company is unchanged from yesterday’s close of $11.15. Company shares last traded at $11.15 slightly over the 50 day moving average which is $11.10 and which is slightly above the 200 day moving average of $10.55. The 50 day moving average went up by +0.50% and the 200 day average went up by +5.68%.
SciClone Pharmaceuticals, Inc. currently has a P/E ratio of 13.75 and market capitalization is 581.93M.
SciClone Pharmaceuticals, Inc. (SciClone), launched on June 26, 2003, is a pharmaceutical company. The Business’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Business’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Business’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL)..